Form 8-K Pacira BioSciences, Inc. For: Feb 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Pacira Pharmaceuticals (PCRX) PT Raised to $67 at BMO Capital
February 28, 2022 8:49 AM ESTBMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $67.00 (from $62.00) while maintaining a Market Perform rating following results.
The analyst commented, "4Q beat although rev. was preannounced, but margin improvement coming through and should accelerate following... More
